Drug-resistant tuberculosis is a major health challenge across much of Africa, but after decades of frustration, a new medicine being pioneered in South Africa could be a major breakthrough. Bedaquiline is being made available to 3,000 people suffering side effects of the usual drug-resistant tuberculosis treatment, or who have developed complete drug resistance.
The early signs are encouraging, doctors say, though bedaquiline hasn't yet been tested in large-scale clinical trials. The new drug, one of the first new tuberculosis antibiotics released in 40 years, was first given to 217 South African patients as part of an early access program.
In the Future, A Simple Blood Test may Accurately Diagnose Tuberculosis
Researchers have identified blood-based bio-markers in patients with active TB. This could lead to new blood-based diagnostics and tools for treatment.
Advertisement
Jennifer Hughes, a 36-year-old British doctor in Cape Town, said she has seen the benefits. Already, word has spread at Hughes's clinic in Khayelitsha, a poor township, and people are coming from all over the city requesting the new drug, developed by US-based pharmaceutical company Janssen.
"Everyone has heard that this is where you get better treatment," said Hughes, who recalls the "really, really happy day" when her first bedaquiline patient was declared tuberculosis-free in November last year.
![New Homeopathic Drug for Treatment of Multi-Drug Resistant Tuberculosis]( "New Homeopathic Drug for Treatment of Multi-Drug Resistant Tuberculosis")
Mumbai based researchers have developed a new homeopathic drug which is likely to add value to the treatment of tuberculosis, including Multi-Drug Resistant Tuberculosis patients.
South Africa has one of the worst tuberculosis epidemics in the world, with more than 1,000 cases per 100,000 people and the department of health describing the rise of drug-resistant tuberculosis as a "major public health problem. We want to get 3,000 patients on bedaquiline this year, and plans are in place to scale up," said Norbert Ndjeka, South Africa's director of the drug-resistant tuberculosis program. "The drugs are already in a number of our facilities. Definitely these drugs will reach the patients."
The treatment is also being used in Russia and has received conditional guidelines from the World Health Organization (WHO). But clinical trials aren't concluded, and the drug can be prohibitively expensive -- factors that have limited its distribution.
- Drug resistance growing -
Ndjeka said South Africa was paying approximately $1,000 per six-month course of bedaquiline, which can run a hefty price tag of up to $30,000 in developed countries.
Globally, drug-resistant tuberculosis cases are growing so fast that last year the WHO warned that rates were at "crisis levels." Tuberculosis, a contagious bacterial infection of the lungs, is one of the world's most deadly diseases, killing 1.5 million people in 2013.
Though promising, experts point out that the new drug is not a silver bullet and has side effects of its own, including liver and heart complications. "The treatment we've got is not great, but we know what the side effects are," said Andrew Black, a pulmonologist at the University of Witwatersrand in Johannesburg. "At the moment we don't know (enough) about the new drug."
On a Wednesday morning in March, Black was on duty at a drug resistant tuberculosis clinic at the Charlotte Maxeke Johannesburg Academic Hospital. Over 20 people were waiting for treatment, all with white masks covering their mouths.
Overhead, ultraviolet lights -- light kills tuberculosis germs -- cast a purple glow on the room. Occasionally, a person let out a hacking cough. While the new drug is welcome, South Africa's ability to combat tuberculosis is held back by an overstretched health care system, said Black.
People often default in their treatment because they have to travel so far to a clinic and miss countless days of work. Still, despite the challenges, Black believes South Africa is making progress.
"We won't know if we're winning for a couple of years," he said, "but it's not like HIV was, we're not ignoring it."
Source: AFP
New Homeopathic Drug for Treatment of Multi-Drug Resistant Tuberculosis
Mumbai based researchers have developed a new homeopathic drug which is likely to add value to the treatment of tuberculosis, including Multi-Drug Resistant Tuberculosis patients.
Advertisement
South Africa has one of the worst tuberculosis epidemics in the world, with more than 1,000 cases per 100,000 people and the department of health describing the rise of drug-resistant tuberculosis as a "major public health problem. We want to get 3,000 patients on bedaquiline this year, and plans are in place to scale up," said Norbert Ndjeka, South Africa's director of the drug-resistant tuberculosis program. "The drugs are already in a number of our facilities. Definitely these drugs will reach the patients."
The treatment is also being used in Russia and has received conditional guidelines from the World Health Organization (WHO). But clinical trials aren't concluded, and the drug can be prohibitively expensive -- factors that have limited its distribution.
- Drug resistance growing -
Ndjeka said South Africa was paying approximately $1,000 per six-month course of bedaquiline, which can run a hefty price tag of up to $30,000 in developed countries.
Globally, drug-resistant tuberculosis cases are growing so fast that last year the WHO warned that rates were at "crisis levels." Tuberculosis, a contagious bacterial infection of the lungs, is one of the world's most deadly diseases, killing 1.5 million people in 2013.
Though promising, experts point out that the new drug is not a silver bullet and has side effects of its own, including liver and heart complications. "The treatment we've got is not great, but we know what the side effects are," said Andrew Black, a pulmonologist at the University of Witwatersrand in Johannesburg. "At the moment we don't know (enough) about the new drug."
On a Wednesday morning in March, Black was on duty at a drug resistant tuberculosis clinic at the Charlotte Maxeke Johannesburg Academic Hospital. Over 20 people were waiting for treatment, all with white masks covering their mouths.
Overhead, ultraviolet lights -- light kills tuberculosis germs -- cast a purple glow on the room. Occasionally, a person let out a hacking cough. While the new drug is welcome, South Africa's ability to combat tuberculosis is held back by an overstretched health care system, said Black.
People often default in their treatment because they have to travel so far to a clinic and miss countless days of work. Still, despite the challenges, Black believes South Africa is making progress.
"We won't know if we're winning for a couple of years," he said, "but it's not like HIV was, we're not ignoring it."
Source: AFP
India Needs Political Will to Tackle Tuberculosis Epidemic
Each year, India has more than 300,000 TB-related deaths and economic losses of $23 billion, making it the country's biggest health crisis.
Advertisement
 Trained Giant Rats Sniff Out Tuberculosis from Sputum Samples in MozambiqueGiant rats are being trained to detect tuberculosis-causing bacteria from rows of sputum samples with their impeccable sense of smell. They can test close to a hundred samples within 30 minutes. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.